Jyoti Malhotra

11.5k total citations · 6 hit papers
147 papers, 7.8k citations indexed

About

Jyoti Malhotra is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jyoti Malhotra has authored 147 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 61 papers in Oncology and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jyoti Malhotra's work include Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (22 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Jyoti Malhotra is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (22 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Jyoti Malhotra collaborates with scholars based in United States, United Kingdom and Italy. Jyoti Malhotra's co-authors include Randal J. Kaufman, Lori L. Isom, Paolo Boffetta, Eva Negri, Matteo Malvezzi, Carlo La Vecchia, Michael Hortsch, Salma K. Jabbour, Hongzhi Miao and Kezhong Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Jyoti Malhotra

138 papers receiving 7.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Cycle or a Double-Edged Sword?

2007 1.3k citations Jyoti Malhotra, Randal J. Kaufman profile →
The endoplasmic reticulum and the unfolded protein response

2007 812 citations Jyoti Malhotra, Randal J. Kaufman profile →
Risk factors for lung cancer worldwide

2016 618 citations Jyoti Malhotra, Matteo Malvezzi et al. European Respiratory Journal profile →
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion

2008 576 citations Jyoti Malhotra, Randal J. Kaufman et al. profile →
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

2021 196 citations Salma K. Jabbour, Gregory Riedlinger et al. profile →
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

2024 102 citations Jyoti Malhotra, David Horne et al. Cancers profile →

Peers

Countries citing papers authored by Jyoti Malhotra

Since Specialization

Citations

This map shows the geographic impact of Jyoti Malhotra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jyoti Malhotra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jyoti Malhotra more than expected).

Fields of papers citing papers by Jyoti Malhotra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jyoti Malhotra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jyoti Malhotra. The network helps show where Jyoti Malhotra may publish in the future.

Co-authorship network of co-authors of Jyoti Malhotra

This figure shows the co-authorship network connecting the top 25 collaborators of Jyoti Malhotra. A scholar is included among the top collaborators of Jyoti Malhotra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jyoti Malhotra. Jyoti Malhotra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma 2025 ·Cancer Research Communications ·Glenn J. Hanna, Gregory M. Coté, Rashmi Chugh, Jacob Thomas, Jyoti Malhotra, Richard E. Cutler, Tressa Hood, (unknown), Elizabeth Olek, Miguel A. Villalona‐Calero	0
2	Treatment Approaches for Oligoprogressive Non-Small Cell Lung Cancer: A Review of Ablative Radiotherapy 2025 ·Cancers ·(unknown), (unknown), Yufei Liu, Ramya Muddasani, (unknown), Ravi Salgia, Terence M. Williams, Jyoti Malhotra, Percy Lee, Arya Amini	0
3	Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors 2024 ·Cancer Immunology Immunotherapy ·Jyoti Malhotra, Subhajyoti De, Kim B. Nguyen, (unknown), Victoria Villaflor	3
4	The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic non-small cell lung cancer. 2024 ·Journal of Clinical Oncology ·Ramya Muddasani, (unknown), (unknown), Isa Mambetsariev, Erminia Massarelli, Michelle Afkhami, Ravi Salgia, Jyoti Malhotra	1
5	Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies. 2024 ·Journal of Clinical Oncology ·(unknown), Jyoti Malhotra, (unknown), Mona Arbab, (unknown), (unknown), Matthew P. Deek, Edward G. Garmey, Daniel A. Hamstra, Mai Anh Huynh, Aryavarta M. S. Kumar, (unknown), Benjamin L. Maughan, (unknown), Nitin Ohri, (unknown), Gregory Vlacich, (unknown), (unknown), Robert Timmerman	4
6	Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers 2024 ·Journal of Managed Care & Specialty Pharmacy ·(unknown), (unknown), (unknown), (unknown), Matthew B. Schabath, Jonathan P. Thompson, Jyoti Malhotra, Noah Federman, Gilbert Ko, (unknown), Neil D. Warnock, Sheldon X. Kong, (unknown), Diana Brixner, David D. Stenehjem	1
7	Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors 2024 ·Cancers ·Jyoti Malhotra, (unknown), Arya Amini, Percy Lee	2
8	Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions 2024 ·Journal of Clinical Medicine ·Pankaj Garg, (unknown), (unknown), Prakash Kulkarni, David Horne, Jyoti Malhotra, Ravi Salgia, (unknown), (unknown)	19
9	Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers 2024 ·JAMA Oncology ·Jyoti Malhotra, Isa Mambetsariev, (unknown), (unknown), Arin Nam, (unknown), Bihong T. Chen, (unknown), Arya Amini, Rimas V. Lukas, Ravi Salgia	2
10	Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR) 2023 ·Annals of Neurology ·Craig M. Zaidman, Crystal M. Proud, Craig M. McDonald, Kelly J. Lehman, (unknown), Stefanie Mason, Alexander P. Murphy, (unknown), Shufang Wang, Carol Reid, (unknown), Christoph Wandel, Sarah Lewis, Jyoti Malhotra, Danielle A. Griffin, Rachael A. Potter, (unknown), Jerry R. Mendell	47
11	Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors 2023 ·Cell Death and Disease ·Vrushank Bhatt, Taijin Lan, Wenping Wang, (unknown), (unknown), Jianming Wang, Khoosheh Khayati, (unknown), (unknown), (unknown), Zhixian Hu, (unknown), Xiaoyang Su, Jyoti Malhotra, Wenwei Hu, Sharon R. Pine, Eileen White, Jessie Yanxiang Guo	33
12	Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience 2023 ·Journal of Clinical Medicine ·Miguel A. Villalona‐Calero, Jyoti Malhotra, Vincent Chung, Yan Xing, Stacy W. Gray, Heather Hampel, Stephen B. Gruber, Kevin McDonnell	0
13	Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma 2022 ·Molecular Therapy ·(unknown), Zhouji Chen, Zu‐Hua Gao, Ruishu Deng, Anthoula Lazaris, Cynthia Lebeaupin, (unknown), Jyoti Malhotra, Jing Yong, Chenhui Zou, Ype P. de Jong, Peter Metrakos, Roland W. Herzog, Randal J. Kaufman	21
14	Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma 2022 ·Molecular Cancer Therapeutics ·(unknown), Saman Zeeshan, Olga B. Garbuzenko, Hatem E. Sabaawy, Jyoti Malhotra, Tamara Minko, Sharon R. Pine	0
15	Montelukast in hospitalized patients diagnosed with COVID-19 2021 ·Journal of Asthma ·Anzalee Khan, (unknown), Nikhil Yegya‐Raman, Sinae Kim, Navaneeth Narayanan, (unknown), Padmini Salgame, Jared Radbel, (unknown), (unknown), Janice M. Mehnert, Caleb Hernandez, Thomas J. Braciale, Jyoti Malhotra, Michael A. Gentile, Salma K. Jabbour	52
16	Combining radiation therapy and immunotherapy for lung cancers: a narrative review 2021 ·Shanghai Chest ·(unknown), Lyudmyla Berim, (unknown), Jyoti Malhotra, (unknown), John Langenfeld, Joseph Aisner, (unknown), Salma K. Jabbour	6
17	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) 2020 ·Clinical Cancer Research ·Erin M. Bertino, Ryan D. Gentzler, (unknown), Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, (unknown), Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie J. Lau, Lynette M. Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard	31
18	Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) 2019 ·Cancer Treatment and Research Communications ·Jyoti Malhotra, Salma K. Jabbour, (unknown), Gregory Riedlinger, Yanxiang Guo, Eileen White, Joseph Aisner	52
19	Risk factors for lung cancer worldwide breakdown → 2016 ·European Respiratory Journal ·Jyoti Malhotra, Matteo Malvezzi, Eva Negri, Carlo La Vecchia, Paolo Boffetta	618
20	Effect of Occupational Exposures on Lung Cancer Susceptibility: A Study of Gene–Environment Interaction Analysis 2015 ·Cancer Epidemiology Biomarkers & Prevention ·Jyoti Malhotra, Samantha Sartori, Paul Brennan, Давид Заридзе, Neonila Szeszenia‐Dąbrowska, Beata Świątkowska, Péter Rudnai, Jolanta Lissowska, Eleonóra Fabiánová, Dana Mateș, Vladimír Bencko, Valérie Gaborieau, Isabelle Stücker, Lenka Foretová, Vladimír Janout, Paolo Boffetta	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact